Perspectives on Fluorinated Pyrimidine Use in Gastrointestinal and Breast Oncology
January 2nd 2001During this symposium, faculty participated in a roundtable discussion of the relative merits and weaknesses associated with use of the fluorinated pyrimidines. Dehydropyrimidine dehydrogenase (DPD) deficiency and the impact of this deficiency on
Perspectives on the Use of Fluorinated Pyrimidines
January 2nd 2001The fluorinated pyrimidines, in particular 5-fluorouracil (5-FU), are among the oldest cytotoxic agents still in broad use today. To some degree, this continued use of 5-FU is a bit of an embarrassment to those of us who spend considerable amounts of
Biochemical Modulation of 5-FU in Systemic Treatment of Advanced Colorectal Cancer
January 2nd 2001Randomized studies have tested a variety of strategies to improve the activity of 5-fluorouracil (5-FU) in colorectal cancer patients. Results from 14 randomized trials comparing 5-FU administered via intravenous ( IV) bolus either
Clinical Status of Capecitabine in the Treatment of Breast Cancer
January 2nd 2001New treatment strategies for advanced breast cancer have focused on both the development of new molecular targets in breast cancer cells, as well as improving the therapeutic index of presently available therapy. The
Other Fluorinated Pyrimidines in the Treatment of Solid Tumors
January 2nd 2001Researchers, primarily in Japan, Europe, and the United States, have evaluated several new fluorinated pyrimidines in recent years. Most of these drugs are orally active prodrugs of fluorouracil (5-FU), and some also
Clinical Implications of Dihydropyrimidine Dehydrogenase on 5-FU Pharmacology
January 2nd 2001Dihydropyrimidine dehydrogenase (DPD) is the initial rate-limiting enzyme in the catabolism of 5-fluorouracil (5-FU), accounting for catabolism of over 85% of an administered dose of 5-FU. DPD plays an important role in
Oral Fluoropyrimidine-Based Combination Therapy in Gastrointestinal Cancer
January 2nd 2001Significant emphasis has been placed recently on designing more effective fluorouracil (5-FU)-based combination protocols for gastrointestinal cancer. Promising results were seen with 5-FU/leucovorin in combination with
Oral Chemotherapy for Colorectal Cancer: Some Economic Considerations
January 2nd 2001In the formal medical curriculum, little has been provided to prepare the clinician for an understanding of the economics of health care. The questions are often far more complicated than they initially appear to be, and the
FDA Approves Arsenic Trioxide for Treatment of Acute Promyelocytic Leukemia
January 1st 2001The injectable form of arsenic trioxide (Trisenox) was recently approved by the US Food and Drug Administration (FDA) for the treatment of patients with a severe form of leukemia-acute promyelocytic leukemia (APL)-whose disease has recurred or who have failed to respond to standard therapy.
High-Fat Diet Not Associated With Increased Estrogen in Postmenopausal Women
January 1st 2001There is no evidence that a high-fat diet predisposes older women to breast cancer, report researchers from Harvard Medical School. It has long been thought that dietary fat can increase production of sex hormones, including estrogen, and
Screening With the Prostate-Specific Antigen Test-Texas, 1997
January 1st 2001Prostate cancer is the second leading cause of cancer-related deaths among men in Texas. From 1990 to 1997, the average annual number of prostate cancer-related deaths in Texas was 1900, and the average annual death rate was 20.9 per
Book Review: Lung Cancer Therapy Annual 2000
January 1st 2001In an era of information "overload" for the practicing oncologist, keeping up with the latest therapies for the many distinct clinical scenarios that arise in daily practice can be quite a challenge. Thus, a concise synthesis of the current knowledge in a field, such as provided in Lung Cancer Therapy Annual 2000 by Drs. Heine Hansen and Paul Bunn, can be quite useful. These authors, whose clinical expertise and contributions to lung cancer therapy are internationally acknowledged, offer a complete review of the literature pertaining to lung cancer therapy from the year 1999, including a review of abstracts from major meetings. A brief summary is provided at the end, outlining standard, accepted strategies based on histologic and stage-by-stage criteria. This text serves as a reference that summarizes the major existing literature, evaluates the strength of the evidence, and makes reasonable recommendations on how to proceed with clinical care.
Medicare Backtracks Further on Average Wholesale Prices
January 1st 2001Medicare payment for chemotherapy administration has been a controversial issue beyond accurate practice expense RVUs; a more inflammatory side of the story involves the cuts in payments to oncologists for drugs they purchase and then administer in their office.
Lung Cancer Vaccine Demonstrates Enhanced Antitumor Immunity
January 1st 2001Ravi Salgia, MD, PhD, and colleagues at Dana-Farber Cancer Center presented an encouraging follow-up report on an initial clinical trial of Cell Genesys’ GVAX lung cancer vaccine at the Ninth World Conference on Lung Cancer in Tokyo,
Minimally Invasive Approach to Esophagectomy May Decrease Morbidity
January 1st 2001Minimally invasive surgery for esophagectomy may lower the morbidity often associated with open esophagectomy, according to a study conducted by surgeons at the University of Pittsburgh Medical Center and published in the September
Oxaliplatin Improves Progression-Free Survival in Patients With Colorectal Cancer
January 1st 2001Ateam of European researchers recently reported that the addition of oxaliplatin to the standard regimen for advanced colorectal cancer of fluorouracil (5-FU) and leucovorin doubled the response to therapy and significantly prolonged progression-free survival, compared to leucovorin and 5-FU alone.
Commentary (Overmoyer): Breast Cancer During Pregnancy
January 1st 2001The care of a pregnant breast cancer patient is a challenging clinical situation that historically has placed the welfare of the mother in conflict with that of the fetus. For the woman in this situation, the emotions usually
Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian Cancer?
January 1st 2001Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the
Is There a Role for Intraperitoneal Chemotherapy in the Management of Ovarian
January 1st 2001Phase I and II clinical trial data have demonstrated the safety, pharmacokinetic advantage, and potential for enhanced cytotoxicity associated with the intraperitoneal administration of antineoplastic agents in the